Xeris Biopharma Reports Cortisol Normalization With Recorlev in Cushing's Syndrome Case Study
Bitget2026/10/15 12:04- Xeris Biopharma announced a Recorlev case study showing normalized cortisol levels with improved cardiometabolic health in a patient with difficult-to-control diabetes.
- The case study is scheduled for presentation at the Cardiometabolic Health Congress on October 15-16, 2026.
- Gvoke research presented October 9, 2026, found a gap between clinicians’ awareness of ready-to-use glucagon prescribing guidelines and actual prescribing practices.
- A real-world analysis characterizing hypothyroidism patients using levothyroxine treatment records and thyroid laboratory data will be presented November 6, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip giant makes a move in the quantum track: Intel (INTC.US) acquires startup Classiq to build a full-stack quantum business
Intel has announced the acquisition of Israeli quantum startup Classiq for an undisclosed amount, with the deal expected to be completed in the first half of 2027. Liwu Chen stated that they will develop a full-stack quantum computing business.
$17 billion acquisition emerges: DoorDash (DASH.US) in advanced talks to acquire Instacart, official announcement expected as early as this week
DoorDash plans to acquire Instacart's parent company Maplebear for approximately $17 billions, with an official announcement expected as early as this week. Maplebear shares rose 7.9%, while DoorDash fell 6.1%. The negotiations may fall through.
Crypto prices
More
